The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future

被引：29

作者：

Hamming, Lisanne C. ^{[1
]}

Slotman, Ben J. ^{[2
]}

Verheul, Henk M. W. ^{[1
]}

Thijssen, Victor L. ^{[2
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, De Boelelaan 1118, NL-1081 HV Amsterdam, Netherlands

[2] Vrije Univ Amsterdam, Med Ctr, Dept Radiat Oncol, De Boelelaan 1118, NL-1081 HV Amsterdam, Netherlands

来源：

ANGIOGENESIS | 2017年 / 20卷 / 02期

关键词：

Angiogenesis; Radiation; Angiostatic drugs; Clinical trials; Cancer; Combination therapy; ADVANCED RECTAL-CANCER; PHASE-II-TRIAL; BEVACIZUMAB PLUS IRINOTECAN; RECOMBINANT HUMAN ENDOSTATIN; RENAL-CELL CARCINOMA; RADIATION-THERAPY; PREOPERATIVE TREATMENT; IONIZING-RADIATION; POSTOPERATIVE; 5-FLUOROURACIL; FRACTIONATED RADIOTHERAPY;

D O I：

10.1007/s10456-017-9546-9

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Although monotherapy with angiostatic drugs is still far from effective, there is abundant evidence that angiostatic therapy can improve the efficacy of conventional treatments like radiotherapy. This has instigated numerous efforts to optimize and clinically implement the combination of angiostatic drugs with radiation treatment. The results from past and present clinical trials that explored this combination therapy indeed show encouraging results. However, current findings also show that the combination has variable efficacy and is associated with increased toxicity. This indicates that combining radiotherapy with angiostatic drugs not only holds opportunities but also provides several challenges. In the current review, we provide an update of the most recent insights from clinical trials that evaluated the combination of angiostatic drugs with radiation treatment. In addition, we discuss the outstanding questions for future studies in order to improve the clinical benefit of combining angiostatic therapy with radiation therapy.

引用

收藏

页码：217 / 232

页数：16

相关论文

共 115 条

[51] Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial [J].

Kennecke, Hagen ;

Berry, Scott ;

Wong, Ralph ;

Zhou, Chen ;

Tankel, Keith ;

Easaw, Jacob ;

Rao, Sanjay ;

Post, Jacqueline ;

Hay, John .

EUROPEAN JOURNAL OF CANCER, 2012, 48 (01) :37-45

[52] Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect [J].

Kleibeuker, Esther A. ;

Fokas, Emmanouil ;

Allen, Philip D. ;

Kersemans, Veerle ;

Griffioen, Arjan W. ;

Beech, John ;

Im, Jaehong H. ;

Smart, Sean C. ;

Castricum, Kitty C. ;

van den Berg, Jaap ;

Schulkens, Iris A. ;

Hill, Sally A. ;

Harris, Adrian L. ;

Slotman, Ben J. ;

Verheul, Henk M. ;

Muschel, Ruth J. ;

Thijssen, Victor L. .

ONCOTARGET, 2016, 7 (47) :76613-76627

[53] Combining radiotherapy with sunitinib: lessons (to be) learned [J].

Kleibeuker, Esther A. ;

ten Hooven, Matthijs A. ;

Verheul, Henk M. ;

Slotman, Ben J. ;

Thijssen, Victor L. .

ANGIOGENESIS, 2015, 18 (04) :385-395

[54] Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction [J].

Kleibeuker, Esther A. ;

ten Hooven, Matthijs A. ;

Castricum, Kitty C. ;

Honeywell, Richard ;

Griffioen, Arjan W. ;

Verheul, Henk M. ;

Slotman, Ben J. ;

Thijssen, Victor L. .

CANCER MEDICINE, 2015, 4 (07) :1003-1015

[55] Combining angiogenesis inhibition and radiotherapy: A double-edged sword [J].

Kleibeuker, Esther A. ;

Griffioen, Arjan W. ;

Verheul, Henk M. ;

Slotman, Ben J. ;

Thijssen, Victor L. .

DRUG RESISTANCE UPDATES, 2012, 15 (03) :173-182

[56] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma [J].

Kreisl, Teri N. ;

Kim, Lyndon ;

Moore, Kraig ;

Duic, Paul ;

Royce, Cheryl ;

Stroud, Irene ;

Garren, Nancy ;

Mackey, Megan ;

Butman, John A. ;

Camphausen, Kevin ;

Park, John ;

Albert, Paul S. ;

Fine, Howard A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :740-745

[57] Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review [J].

Kroeze, Stephanie G. C. ;

Fritz, Corinna ;

Hoyer, Morten ;

Lo, Simon S. ;

Ricardi, Umberto ;

Sahgal, Arjun ;

Stahel, Rolf ;

Stuppf, Roger ;

Guckenberger, Matthias .

CANCER TREATMENT REVIEWS, 2017, 53 :25-37

[58] Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer [J].

Kuusk, Teele ;

Albiges, Laurence ;

Escudier, Bernard ;

Grivas, Nikolaos ;

Haanen, John ;

Powles, Thomas ;

Bex, Axel .

ANGIOGENESIS, 2017, 20 (02) :205-215

[59] Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme [J].

Lai, Albert ;

Tran, Anh ;

Nghiemphu, Phioanh L. ;

Pope, Whitney B. ;

Solis, Orestes E. ;

Selch, Michael ;

Filka, Emese ;

Yong, William H. ;

Mischel, Paul S. ;

Liau, Linda M. ;

Phuphanich, Surasak ;

Black, Keith ;

Peak, Scott ;

Green, Richard M. ;

Spier, Cynthia E. ;

Kolevska, Tatjana ;

Polikoff, Jonathan ;

Fehrenbacher, Louis ;

Elashoff, Robert ;

Cloughesy, Timothy .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) :142-148

[60] Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204 [J].

Landry, Jerome C. ;

Feng, Yang ;

Prabhu, Roshan S. ;

Cohen, Steven J. ;

Staley, Charles A. ;

Whittington, Richard ;

Sigurdson, Elin Ruth ;

Nimeiri, Halla ;

Verma, Udit ;

Benson, Al Bowen .

ONCOLOGIST, 2015, 20 (06) :615-616

← 1 2 3 4 5 6 7 8 9 10 →